Aktuelle smitsomme sygdomme
Søgeord (prep) valgt.
10 emner vises.
Jantien A Backer, Eric R A Vos, Gerco den Hartog, Cheyenne C E van Hagen, Hester E de Melker, Fiona R M van der Klis and Jacco Wallinga
Eurosurveillance latest updates, 26.10.2024
Tilføjet 26.10.2024
BackgroundThe first wave of the COVID-19 pandemic in 2020 was largely mitigated by limiting contacts in the general population. In early 2022, most contact-reducing measures were lifted. AimTo assess whether the population has reverted to pre-pandemic contact behaviour and how this would affect transmission potential of a newly emerging pathogen. MethodsWe compared two studies on contact behaviour in the Netherlands: the PIENTER Corona study, conducted during and after the pandemic (held every 2–6 months from April 2020) and the PIENTER3 study (2016–17, as pre-pandemic baseline). In both, participants (ages 1–85 years) reported number and age group of all face-to-face persons contacted on the previous day in a survey. Transmission potential was examined using the next-generation matrix approach. ResultsWe found an average of 15.4 (95% CI: 14.3–16.4) community contacts per person per day after the pandemic in May 2023, 13% lower than baseline (17.8; 95% CI: 17.0–18.5). Among all ages, children (5–9 years) had the highest number of contacts, both pre- and post-pandemic. Mainly adults aged 20–59 years had not reverted to pre-pandemic behaviours, possibly because they more often work from home. Although the number of contacts is lower compared to the pre-pandemic period, the effect on transmission potential of a newly emerging respiratory pathogen is limited if all age groups were equally susceptible. ConclusionContinuous monitoring of contacts can signal changes in contact patterns and can define a ‘new normal’ baseline. Both aspects are needed to prepare for a future pandemic.
Læs mereMedscape Infectious Diseases, 21.10.2024
Tilføjet 21.10.2024
Large study showed current statistical trends of PrEP access vs PrEP need. Medscape Medical News
Læs mereErik Lundgren, Macauley Locke, Ethan Romero-Severson, Mira Dimitrijevic, Maria Axelsson, Emmi Andersson, Christina Carlander, Johanna Brännström, Hans Norrgren, Fredrik Mansson, Olof Elvstam, Magnus Gisslén, Lisa Fohlin, Anders Sönnerborg, Jan Albert and Thomas Leitner
Eurosurveillance latest updates, 18.10.2024
Tilføjet 18.10.2024
BackgroundSweden reached the UNAIDS 90–90–90 target in 2015. It is important to reassess the HIV epidemiological situation due to ever-changing migration patterns, the roll-out of PrEP and the impact of the COVID-19 pandemic. AimWe aimed to assess the progress towards the UNAIDS 95–95–95 targets in Sweden by estimating the proportion of undiagnosed people with HIV (PWHIV) and HIV incidence trends. MethodsWe used routine laboratory data to inform a biomarker model of time since infection. When available, we used previous negative test dates, arrival dates for PWHIV from abroad and transmission modes to inform our incidence model. We also used data collected from the Swedish InfCareHIV register on antiretroviral therapy (ART). ResultsThe yearly incidence of HIV in Sweden decreased after 2014. In part, this was because the fraction of undiagnosed PWHIV had decreased almost twofold since 2006. After 2015, three of four PWHIV in Sweden were diagnosed within 1.9 and 3.2 years after infection among men who have sex with men and in heterosexual groups, respectively. While 80% of new PWHIV in Sweden acquired HIV before immigration, they make up 50% of the current PWHIV in Sweden. By 2022, 96% of all PWHIV in Sweden had been diagnosed, and 99% of them were on ART, with 98% virally suppressed. ConclusionsBy 2022, about half of all PWHIV in Sweden acquired HIV abroad. Using our new biomarker model, we assess that Sweden has reached the UNAIDS goal at 96–99–98.
Læs mereRobert Dyrdak, Emma B Hodcroft, Sandra Broddesson, Malin Grabbe, Hildur Franklin, Magnus Gisslén, Maricris E Holm, Magnus Lindh, Joanna Nederby-Öhd, Johan Ringlander, Martin Sundqvist, Richard A Neher and Jan Albert
Eurosurveillance latest updates, 11.10.2024
Tilføjet 11.10.2024
BackgroundDespite the unprecedented measures implemented globally in early 2020 to prevent the spread of SARS-CoV-2, Sweden, as many other countries, experienced a severe first wave during the COVID-19 pandemic. AimWe investigated the introduction and spread of SARS-CoV-2 into Sweden. MethodsWe analysed stored respiratory specimens (n = 1,979), sampled 7 February–2 April 2020, by PCR for SARS-CoV-2 and sequenced PCR-positive specimens. Sequences generated from newly detected cases and stored positive specimens February–June 2020 (n = 954) were combined with sequences (Sweden: n = 730; other countries: n = 129,913) retrieved from other sources for Nextstrain clade assignment and phylogenetic analyses. ResultsTwelve previously unrecognised SARS-CoV-2 cases were identified: the earliest was sampled on 3 March, 1 week before recognised community transmission. We showed an early influx of clades 20A and 20B from Italy (201/328, 61% of cases exposed abroad) and clades 19A and 20C from Austria (61/328, 19%). Clade 20C dominated the first wave (20C: 908/1,684, 54%; 20B: 438/1,684, 26%; 20A: 263/1,684, 16%), and 800 of 1,684 (48%) Swedish sequences formed a country-specific 20C cluster defined by a spike mutation (G24368T). At the regional level, the proportion of clade 20C sequences correlated with an earlier weighted mean date of COVID-19 deaths. ConclusionCommunity transmission in Sweden started when mitigation efforts still focused on preventing influx. This created a transmission advantage for clade 20C, likely introduced from ongoing cryptic spread in Austria. Therefore, pandemic preparedness should have a comprehensive approach, including capacity for large-scale diagnostics to allow early detection of travel-related cases and community transmission.
Læs mereElena Pariani, Antonio Piralla, Laura Pellegrinelli, Federica Giardina, Vincenzo Navobi Porrello, Greta Romano, Cristina Galli, Laura Sandri, Guglielmo Ferrari, Sandro Binda, Luigi Vezzosi, Gabriele Del Castillo, Sabrina Buoro, Danilo Cereda, Fausto Baldanti and Respiratory viruses pandemic preparedness group Lombardy
Eurosurveillance latest updates, 11.10.2024
Tilføjet 11.10.2024
We report a considerable increase in enterovirus D68 (EV-D68) cases since July 2024, culminating in an ongoing outbreak of acute respiratory infections in northern Italy, accounting for nearly 90% of all enterovirus infections. The outbreak was identified by community- and hospital-based surveillance systems, detecting EV-D68 in individuals with mild-to-severe respiratory infections. These strains belonged to B3 and a divergent A2 lineage. An increase in adult cases was observed. Enhanced surveillance and molecular characterisation of EV-D68 across Europe are needed.
Læs mereVita W Jongen, Daniela Bezemer, Ard van Sighem, Anders Boyd, Casper Rokx, Karin Grintjes, Aafke Cents-Bosma, Eline Op de Coul, Birgit van Benthem, Annemarie Wensing, Ferdinand WNM Wit, Marc van der Valk and on behalf of the ATHENA national observational HIV cohort
Eurosurveillance latest updates, 20.09.2024
Tilføjet 20.09.2024
BackgroundIn the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known. AimWe assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands. MethodsData on prior PrEP use between 1 January 2018 and 31 December 2022 were available from the Dutch national ATHENA cohort. We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree. ResultsData on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. We found no evidence of onward transmission of PrEP RAMs. ConclusionThe prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections.
Læs mereMedscape Infectious Diseases, 17.09.2024
Tilføjet 17.09.2024
The UK government has ordered more than 150,000 doses of Bavarian Nordic\'s mpox vaccine to boost its preparedness against a new form of the virus currently spreading in... Reuters Health Information
Læs mereFlorian Gehre, Eric Nzeyimana, Hakim Idris Lagu, Emmanuel Achol, Julien A Nguinkal, Eric Kezakarayagwa, Théogene Ihorimbere, Néhémie Nzoyikorera, Francine Kabatesi, Marie-Noelle Uwineza, Abdi Roba, Millicent Nyakio Ndia, John Ndemi Kiiru, Gwokpan Awin Nykwec, Isaac Gatkuoth Chot Moun, Mamdouh A Aguer, James A Maror, Gregory Wani Dumo, Michael Losuba, Lul Lojok Deng, Neema Omari, Grace Ochido, Aryse Martins Melo, Peter Bernard Mtesigwa Mkama, Edna Mgimba, Monica Fredrick Francis, Lawrence A Mapunda, Alex Magesa, Nyambura Moremi, Godfrey Pimundu, Tonny Muyigi, Susan Ndidde Nabadda, Emmanuel Kabalisa, Isabelle Mukagatare, Daniel Mukadi-Bamuleka, Erick Ntambwe Kamangu, Jürgen May and Muna Affara
Eurosurveillance latest updates, 30.08.2024
Tilføjet 30.08.2024
The East African Community (EAC) is experiencing an unprecedented, emerging mpox outbreak since July 2024 in five of eight partner states. We highlight rapid regional response measures, initiated August 2024 coordinated by EAC: field deployment of six mobile laboratories in Burundi, Rwanda, Uganda, Tanzania, Kenya, South Sudan to high-risk areas, donation of one mobile laboratory to Democratic Republic of the Congo and genomic monkeypox virus (MPXV) surveillance support. These interventions aim to limit local mpox spread and support international containment.
Læs merePhillip Zucs, Julien Beauté, Daniel Palm and Gianfranco Spiteri
Eurosurveillance latest updates, 23.08.2024
Tilføjet 23.08.2024
This perspective summarises and explains the long-term surveillance framework 2021–2027 for infectious diseases in the European Union/European Economic Area (EU/EEA) published in April 2023. It shows how shortcomings in the areas of public health focus, vigilance and resilience will be addressed through specific strategies in the coming years and how these strategies will lead to stronger surveillance systems for early detection and monitoring of public health threats as well as informing their effective prevention and control. A sharper public health focus is expected from a more targeted list of notifiable diseases, strictly public-health-objective-driven surveillance standards, and consequently, leaner surveillance systems. Vigilance should improve through mandatory event reporting, more automated epidemic intelligence processing and increased use of genomic surveillance. Finally, EU/EEA surveillance systems should become more resilient by modernising the underlying information technology infrastructure, expanding the influenza sentinel surveillance system to other respiratory viruses for better pandemic preparedness, and increasingly exploiting potentially more robust alternative data sources, such as electronic health records and wastewater surveillance. Continued close collaboration across EU/EEA countries will be key to ensuring the full implementation of this surveillance framework and more effective disease prevention and control.
Læs mereMedscape Infectious Diseases, 22.08.2024
Tilføjet 22.08.2024
Preexposure prophylaxis prescription reversals and abandonments were lower for patients seen by primary care clinicians than by other noninfectious disease clinicians. MDedge News
Læs mere